Max Robotics — Global Service Robot Directory + US Certification

About

Masatoshi Kitakaze is a leading surgical oncologist whose research centers on advanced gastric and gastroesophageal junction cancers, with a particular focus on precision medicine and minimally invasive surgical techniques. His most impactful work investigates the real-world efficacy and safety of zolbetuximab, a targeted therapy for CLDN18.2-positive tumors, as highlighted in his 2025 study on protein-losing enteropathy—a critical adverse event observed in patients from the landmark GLOW and SPOTLIGHT trials. This paper, with 13 citations, underscores his commitment to translating clinical trial findings into practical, patient-centered care. Kitakaze has also made significant contributions to comparative surgical outcomes, demonstrating in a 2025 study (10 citations) that robotic and laparoscopic gastrectomy yield comparable perioperative performance and three-year survival rates, advancing the evidence base for robotic surgery in gastric cancer. Additionally, his work on conversion surgery following zolbetuximab-based chemotherapy offers new hope for patients with initially unresectable disease. Through these contributions, Kitakaze has shaped both the pharmacological and surgical management of gastric cancer, earning recognition as a key figure in oncologic surgery.